Trials / Completed
CompletedNCT04091061
Effect Of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of PF-06865571 In Subjects With Hepatic Impairment and in Healthy Subjects
A PHASE 1, NON-RANDOMIZED, OPEN-LABEL, SINGLE-DOSE, PARALLEL-COHORT STUDY TO COMPARE THE PHARMACOKINETICS OF PF 06865571 IN ADULT PARTICIPANTS WITH VARYING DEGREES OF HEPATIC IMPAIRMENT RELATIVE TO PARTICIPANTS WITHOUT HEPATIC IMPAIRMENT
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
The current study is proposed to evaluate whether there is any clinically meaningful effect of hepatic impairment on the plasma PK of PF-06865571.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PF-06865571 100 mg | PF-06865571 in 100 mg oral tablet will be administered on Day 1 |
Timeline
- Start date
- 2019-10-03
- Primary completion
- 2020-04-07
- Completion
- 2020-04-07
- First posted
- 2019-09-16
- Last updated
- 2021-04-13
- Results posted
- 2021-04-13
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04091061. Inclusion in this directory is not an endorsement.